Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Stephanie Drewery"'
Autor:
Scott A. Tomlins, Nickolay A. Khazanov, Benjamin J. Bulen, Daniel H. Hovelson, Melissa J. Shreve, Laura E. Lamb, Marc R. Matrana, Mark E. Burkard, Eddy Shih-Hsin Yang, William Jeffery Edenfield, E. Claire Dees, Adedayo A. Onitilo, Michael Thompson, Gary L. Buchschacher, Alan M. Miller, Alexander Menter, Benjamin Parsons, Timothy Wassenaar, Leon C. Hwang, J. Marie Suga, Robert Siegel, William Irvin, Suresh Nair, Jennifer N. Slim, Jamal Misleh, Jamil Khatri, Gregory Masters, Sachdev Thomas, Malek Safa, Daniel M. Anderson, Kat Kwiatkowski, Khalis Mitchell, Tina Hu-Seliger, Stephanie Drewery, Andrew Fischer, Komal Plouffe, Eric Czuprenski, Jennifer Hipp, Travis Reeder, Hana Vakil, D. Bryan Johnson, Daniel R. Rhodes
Publikováno v:
Communications Medicine, Vol 3, Iss 1, Pp 1-14 (2023)
Tomlins et al. develop an Immunotherapy Response Score (IRS) to predict clinical benefit from checkpoint inhibition across solid tumors. IRS integrates TMB and gene expression, is evaluable from FFPE material, and is predictive for real-world progres
Externí odkaz:
https://doaj.org/article/4592ab4c5780454fabd8956daa3f8f79
Autor:
Nickolay Khazanov, Melissa Shreve, Laura Lamb, Daniel Hovelson, Marc Matrana, Mark Burkard, Eddy Yang, William Edenfield, Claire Dees, Adedayo Onitilo, Michael Thompson, Gary Buchschacher, Alan Miller, Alexander Menter, Benjamin Parsons, Timothy Wassenaar, Leon Hwang, J. Suga, Robert Siegel, William Irvin, Suresh Nair, Jennifer Slim, Kat Kwiatkowski, Khalis Mitchell, Tina Hu-Seliger, Stephanie Drewery, Andrew Fischer, Jennifer Hipp, Travis Reeder, Hana Vakil, Bryan Johnson, Daniel Rhodes, Scott Tomlins
Pembrolizumab is approved in many advanced solid tumor types, however predictive biomarkers and the proportion of pembrolizumab-benefiting patients vary. Biomarkers beyond PD-L1 immunohistochemistry, microsatellite instability (MSI) status, and tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d44f832c2a2425bf32a36e8fa251391
https://doi.org/10.21203/rs.3.rs-1225960/v1
https://doi.org/10.21203/rs.3.rs-1225960/v1
Autor:
Daniel R. Rhodes, D. Bryan Johnson, Travis Reeder, Kat Kwiatkowski, Daniel H. Hovelson, Jennifer Hipp, Jayson Falkner, Hana Vakil, Lorena Lazo de la Vega, Stephanie Drewery, Khalis Mitchell, Javed Siddiqui, Paul W. Harms, Andrew H. Fischer, Scott A. Tomlins
Publikováno v:
The Journal of molecular diagnostics : JMD. 23(11)
Despite widespread use in targeted tumor testing, multiplex PCR/semiconductor (Ion Torrent) sequencing-based assessment of all comprehensive genomic profiling (CGP) variant classes has been limited. Herein, we describe the development and validation